Skip to content

Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention

A Randomized Comparison Between Transfemoral Approach With Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02831166
Acronym
ARISE-2
Enrollment
250
Registered
2016-07-13
Start date
2016-01-31
Completion date
2019-11-30
Last updated
2020-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications; Device, Vascular, Injury; Blood Vessel, Femoral, Artery, Injury of Radial Artery, Myocardial Infarction

Keywords

Vascular closure devices, Transradial approach, Transfemoral approach

Brief summary

Primary percutaneous coronary intervention represents the gold standard for the treatment of ST-segment-elevation acute myocardial infarction. However, periprocedural bleedings are associated with an increased risk of mortality, re-infarction, and stroke. Although the prognostic value of access site related bleeding complications is still debated, transradial approach is associated with better short-term outcomes and reduced hospital stay as compared to transfemoral approach. The investigators aimed to compare transradial approach with transfemoral approach with systematic achievement of hemostasis by the implantation of a vascular closure device in a national multicentre randomized clinical trial.

Interventions

PROCEDURETransradial primary percutaneous coronary intervention

Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.

PROCEDURETransfemoral primary percutaneous coronary intervention

Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.

Sponsors

Irmandade Santa Casa Misericórdia Marília
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset; * Intention to perform primary percutaneous coronary intervention; * Signed informed consent; * Patient eligible for transradial and transfemoral primary percutaneous coronary intervention, being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process.

Exclusion criteria

* Less than 18 years of age; * Pregnancy; * Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists; * Hypersensitivity to antiplatelet and/or anticoagulant drugs; * Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance \< 30 mL/min, platelets count \< 100.000 mm3); * Uncontrolled systemic hypertension; * Cardiogenic shock; * Previous myocardial revascularization surgery with ≥ 1 internal mammary or radial artery graft; * Documented chronic peripheral arterial disease preventing the use of the femoral technique; * Severe concomitant disease with life expectancy below 12 months; * Participation in drug or devices investigative clinical trials in the last 30 days; * Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term.

Design outcomes

Primary

MeasureTime frameDescription
Major vascular access site complications48 hours post-procedureMajor vascular complications related to arterial access site will be evaluated during hospitalization by physical examination and duplex ultrassonography and include major bleeding, retroperitoneal hemorrhage, compartment syndrome, pseudoaneurysm, arteriovenous fistula, limb ischemia or need for vascular surgery repair.

Secondary

MeasureTime frameDescription
Device success48 hours post-procedureThe success of the device is defined as the attainment of adequate hemostasis at the end of the procedure, without the need to apply other compression methods.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026